Celyad Oncology SA (NASDAQ:CYAD – Get Rating) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.88 and traded as low as $1.79. Celyad Oncology shares last traded at $1.79, with a volume of 8,115 shares.
Celyad Oncology Stock Performance
The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.58 and a current ratio of 1.71. The stock's 50 day simple moving average is $1.88 and its two-hundred day simple moving average is $2.08.
About Celyad Oncology
(Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
Featured Articles
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
在週四的交易中,Celyad Oncology SA(納斯達克代碼:Cyad-Get Rating)的股價跌破了50日移動均線。該股的50日移動均線為1.88美元,交易價格低至1.79美元。Celyad Oncology的股票最後交易價格為1.79美元,成交量為8,115股。
Celyad腫瘤學股票表現
該公司的負債權益比率為0.05,速動比率為2.58,流動比率為1.71。該股的50日簡單移動均線切入位為1.88美元,200日簡單移動均線切入位為2.08美元。
關於Celyad腫瘤學
(獲取評級)
Celyad Oncology SA是一家臨床階段的生物製藥公司,專注於發現和開發用於癌症治療的嵌合抗原受體T(CAR-T)細胞療法。它的主要候選產品包括用於治療轉移性結直腸癌的同種異體CAR-T候選藥物Cyad-101,處於1b期臨床試驗的轉移性結直腸癌;基於短髮夾狀RNA(ShRNA)的同種異體CAR-T候選藥物,正處於治療復發/難治性多發性骨髓瘤的第一階段臨床試驗;以及正在進行第一階段臨床試驗的自體CAR-T候選藥物Cyad-02,用於治療復發或難治性急性髓系白血病和骨髓增生異常綜合徵。
專題文章
- 免費獲取StockNews.com關於Celyad腫瘤學的研究報告(CyAD)
- 隨著管理層重組,股市能否迅速反彈?
- MarketBeat:回顧中的一週8/29-9/2
- 霍梅爾在這些水準上看起來很便宜
- Lululemon將躍升至9月
- 耐克股票會被超賣,但仍被高估嗎?
接受Celyad腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Celyad Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。